Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Mar 5, 2025
Emerging Company Profile
Bambusa: Combining validated I&I targets in bispecifics to broaden efficacy
With $105M in venture funding, Bambusa has moved quickly towards the clinic with bispecifics in-licensed from antibody powerhouse Biotheus
BioCentury | Feb 21, 2025
Emerging Company Profile
Glen Clova: Fighting autoimmunity with cytokine-carrying virus-like particles
Glasgow-based company betting VLPs can beat biologics on price, dosing and safety for autoimmune and allergic diseases
BioCentury | Jan 6, 2025
Regulation
2024 Approvals: Where are the new modalities?
Last year’s new drug approvals by FDA reflect the continued focus on best-in-class drug development
BioCentury | Nov 1, 2024
Finance
How Fairmount’s Paragon incubator steered two more companies to NASDAQ
In BioCentury’s Public Equity Report: Paragon-backed Jade and Crescent each reverse-merging with public companies, raising combined $500M
BioCentury | Oct 16, 2024
Data Byte
Trio of indications for Bimzelx among FDA’s September label expansions
Agency converts accelerated approvals of Filspari and Retevmo to full
BioCentury | Sep 25, 2024
Product Development
Dermatitis data underwhelm, but Amgen sees possible ‘practice-changing’ asset for myasthenia gravis
Uplizna’s Phase III data in myasthenia gravis impress; rocatinlimab’s results less strong but a new MoA may still have a play in atopic dermatitis
BioCentury | Sep 5, 2024
Data Byte
FDA’s new drug approvals in August include a Dupixent competitor, a targeted glioma therapy, and more
Agency approved seven new therapies in August, plus four new product formulations or dosages
BioCentury | Jun 1, 2024
Data Byte
EMA’s CHMP recommends new indications for Dupixent, Skyrizi
May decisions also include CStone’s PD-1 inhibitor and Pfizer’s Factor IX gene therapy
BioCentury | May 22, 2024
Product Development
Clinical Report: GSK records asthma win
Plus: Data from Amgen-AstraZeneca, Biogen-Ionis and more
Items per page:
1 - 10 of 175